Prostatic diseasesAdverse Impact of Sexual Dysfunction in Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Section snippets
Participants and Clinical Evaluation
The participants were recruited from the general urology clinics in Penang, Malaysia from February 1, 2004 to October 10, 2005, after the men provided informed consent according to the protocols approved by the Joint School of Pharmaceutical Sciences, University of Science Malaysia-Penang Hospital and University of Washington institutional review boards. The evaluation followed a standardized clinical and microbiologic protocol. All met the National Institutes of Health CP/CPPS definition.1 In
Participants
Of the 389 patients with CP/CPPS screened, 296 enrolled, representing a 76% response rate. The participants were an average of 41.4 ± 10.6 years old (range 20 to 69), had a mean symptom duration of 2.0 ± 2.8 years (range 3 months to 23 years), and a mean NIH-CPSI total score of 21.9 ± 7.2 (range 0 to 41; Table 2). Most were employed (86%), were married or living with a partner (74%), and had received at least one previous treatment for CP/CPPS symptoms (69%).
Prevalence and Impact of Sexual Dysfunction
Of the 296 participants, 214 (72.3%)
Comment
Self-reported sexual dysfunction occurred in almost three quarters of our 296 participants with CP/CPPS. Among the 214 men with sexual dysfunction, 54 (25.0%) complained of ED only, 71 (33.4%) of ejaculatory difficulties only, and 89 (41.6%) of both ED and ejaculatory difficulties. A multinational study evaluated ED in random samples of 600 men from each of multiple countries using a standardized questionnaire.15 Age-adjusted rates of moderate or severe ED were 22% in Malaysia, 34% in Japan,
Conclusions
Sexual dysfunction was self-reported by almost three quarters of our population of 296 men with CP/CPPS. Patients with sexual dysfunction were more likely to report the combination of ED and ejaculatory difficulties (41.6%) than ejaculatory difficulties only (33.4%) or ED only (25.0%). Sexual dysfunction, especially the combination of ED and ejaculatory difficulties, was associated with substantial reductions in QOL (P = 0.006) and worse CP/CPPS symptoms (P = 0.042). These findings suggest that
Acknowledgment
To the consultant urologists and primary care physicians in the northern Malaysian states who referred patients for this study, especially Drs. Christopher Chee, Hin Wai Yap, Wooi Long Choong, Timothy Khor, Chu Leong Teh, and Murali Mohan, with great appreciation for their support; and to Kok Heng Heng, Siew Kin Yang, Colina Wong, Mai Chuan Heng, Beng Sim Lee, Nohana Arif, and Ms. Pushpa for their assistance in data acquisition and clinical work.
References (26)
- et al.
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial
J Urol
(2003) - et al.
Chronic pelvic pains represent the most prominent urogenital symptoms of “chronic prostatitis”
Urology
(1996) - et al.
Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial
J Urol
(2003) - et al.
Levofloxacin for chronic prostatitis/chronic pelvic pain syndrome in men: a randomized placebo-controlled multicenter trial
Urology
(2003) - et al.
Demographic and clinical characteristics of men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study
J Urol
(2002) - et al.
Chronic prostatitis: symptom survey with follow-up clinical evaluation
Urology
(2003) - et al.
The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction
Urology
(1997) - et al.
Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction
Urology
(2003) - et al.
Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training
J Urol
(2006) - et al.
CPCRN Study Group: Impact of post-ejaculatory pain in men with category III chronic prostatitis/chronic pelvic pain syndrome (CPPS)
J Urol
(2004)
A review of the development and validation of the National Institutes of Health Chronic Prostatitis Symptom Index
Urology
Demographic and clinical characteristics of chronic prostatitis: prospective comparison of the University of Sciences Malaysia cohort with the U.S. National Institute of Health cohort
J Urol
Demographic and clinical characteristics of men with chronic prostatitis: the National Institutes of Health Chronic Prostatitis Cohort Study
J Urol
Cited by (76)
Predictors of Male Sexual Dysfunction in Urologic Chronic Pelvic Pain Syndrome (UCPPS), Other Chronic Pain Syndromes, and Healthy Controls in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network
2022, Journal of Sexual MedicineCitation Excerpt :Sexual dysfunction (SD), including erectile dysfunction (ED), ejaculatory disorders, and suppressed libido, is prevalent among patients with UCPPS and is associated with a diminished quality of life (QoL).3–7 Several mechanisms have been proposed including the influence of associated psychological conditions, endothelial dysfunction, and the destructive effects of the inflammatory response.3,8–12 The current literature is limited by small sample sizes, inconsistent objective evaluations, and lack of control groups.2
The impact of nonmotor symptom burden on sexual function
2022, International Review of NeurobiologyCitation Excerpt :Chronic pelvic pain has been linked to SD in men (Lee et al., 2008). Of the participants of this particular study, 48.3% reported erectile dysfunction, which was linked with severity of pain in these patients (Lee et al., 2008). SD is also associated with urinary dysfunction (Vela-Desojo et al., 2020).
THE ACUPUNCTURE IN CHRONIC PROSTATITIS/ CHRONIC PELVIC PAIN, RETROSPECTIVE COMPARATIVE STUDY
2023, Community PractitionerChronic prostatitis/chronic pelvic pain syndrome
2023, Urologie
This study was funded in part by the U.S. National Institutes of Health, Bethesda, Maryland, grants DK065266 and DK38955.